These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 32213878)
1. Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes. Kim Y; Gil J; Pla I; Sanchez A; Betancourt LH; Lee B; Appelqvist R; Ingvar C; Lundgren L; Olsson H; Baldetorp B; Kwon HJ; Oskolás H; Rezeli M; Doma V; Kárpáti S; Szasz AM; Németh IB; Malm J; Marko-Varga G Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32213878 [TBL] [Abstract][Full Text] [Related]
5. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. Olszanski AJ J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639 [TBL] [Abstract][Full Text] [Related]
6. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy? Kelley MC Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005 [TBL] [Abstract][Full Text] [Related]
7. BRAF Mutations in Melanoma: Biological Aspects, Therapeutic Implications, and Circulating Biomarkers. Castellani G; Buccarelli M; Arasi MB; Rossi S; Pisanu ME; Bellenghi M; Lintas C; Tabolacci C Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627054 [TBL] [Abstract][Full Text] [Related]
8. The Hidden Story of Heterogeneous B-raf V600E Mutation Quantitative Protein Expression in Metastatic Melanoma-Association with Clinical Outcome and Tumor Phenotypes. Betancourt LH; Szasz AM; Kuras M; Rodriguez Murillo J; Sugihara Y; Pla I; Horvath Z; Pawłowski K; Rezeli M; Miharada K; Gil J; Eriksson J; Appelqvist R; Miliotis T; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Horvatovich P; Welinder C; Wieslander E; Kwon HJ; Malm J; Nemeth IB; Jönsson G; Fenyö D; Sanchez A; Marko-Varga G Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31835364 [TBL] [Abstract][Full Text] [Related]
9. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma. Kiniwa Y; Okuyama R Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202 [TBL] [Abstract][Full Text] [Related]
10. MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors. Grimaldi AM; Simeone E; Festino L; Vanella V; Strudel M; Ascierto PA Am J Clin Dermatol; 2017 Dec; 18(6):745-754. PubMed ID: 28537004 [TBL] [Abstract][Full Text] [Related]
11. Plasma proteome alterations by MAPK inhibitors in BRAF Babačić H; Eriksson H; Pernemalm M Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984 [TBL] [Abstract][Full Text] [Related]
12. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286 [TBL] [Abstract][Full Text] [Related]
13. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF Torres-Collado AX; Knott J; Jazirehi AR Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29795041 [TBL] [Abstract][Full Text] [Related]
14. Clinical protein science in translational medicine targeting malignant melanoma. Gil J; Betancourt LH; Pla I; Sanchez A; Appelqvist R; Miliotis T; Kuras M; Oskolas H; Kim Y; Horvath Z; Eriksson J; Berge E; Burestedt E; Jönsson G; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Horvatovich P; Murillo JR; Sugihara Y; Welinder C; Wieslander E; Lee B; Lindberg H; Pawłowski K; Kwon HJ; Doma V; Timar J; Karpati S; Szasz AM; Németh IB; Nishimura T; Corthals G; Rezeli M; Knudsen B; Malm J; Marko-Varga G Cell Biol Toxicol; 2019 Aug; 35(4):293-332. PubMed ID: 30900145 [TBL] [Abstract][Full Text] [Related]
15. Molecular Features of Resected Melanoma Brain Metastases, Clinical Outcomes, and Responses to Immunotherapy. Vasudevan HN; Delley C; Chen WC; Mirchia K; Pan S; Shukla P; Aabedi AA; Nguyen MP; Morshed RA; Young JS; Boreta L; Fogh SE; Nakamura JL; Theodosopoulos PV; Phillips J; Hervey-Jumper SL; Daras M; Pike L; Aghi MK; Tsai K; Raleigh DR; Braunstein SE; Abate AR JAMA Netw Open; 2023 Aug; 6(8):e2329186. PubMed ID: 37589977 [TBL] [Abstract][Full Text] [Related]
16. Pluripotency markers are differentially induced by MEK inhibition in thyroid and melanoma BRAFV600E cell lines. Dorris ER; Blackshields G; Sommerville G; Alhashemi M; Dias A; McEneaney V; Smyth P; O'Leary JJ; Sheils O Cancer Biol Ther; 2016 May; 17(5):526-42. PubMed ID: 26828826 [TBL] [Abstract][Full Text] [Related]
17. NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma. Flockhart RJ; Armstrong JL; Reynolds NJ; Lovat PE Br J Cancer; 2009 Oct; 101(8):1448-55. PubMed ID: 19724275 [TBL] [Abstract][Full Text] [Related]
18. Emerging treatment options for Ursem C; Atreya CE; Van Loon K Gastrointest Cancer; 2018; 8():13-23. PubMed ID: 29628780 [TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290 [TBL] [Abstract][Full Text] [Related]